The national drug price regulator National Pharmaceutical Pricing Authority (NPPA) unearthed a total of 613 cases of non-compliance of its notified price ceilings of various drugs by companies.
Since after setting stent ceiling prices on February 14, 2017, the drug price regulator has so far received 40 written complaints against major hospitals.
National drug pricing authority NPPA has identified 634 cases where non-compliance with the notified price ceilings is suspected, Parliament has been informed.
More than 20 medical devices that are notified as "drugs" must all carry the maximum retail price on packages, the NPPA drug price regulator said. These devices include cardiac valves, surgical dressings, condoms, stents, disposable hypodermic syringes and orthopedic implants.
The NPPA drug price regulator has reduced the prices of anticancer drugs by almost 86% since last March to relieve patients. There has been "a significant reduction in the prices of cancer drugs since March 2016," said the National Pharmaceutical Pricing Authority (NPPA) in a tweet.
National Pharmaceutical Pricing Authority (NPPA) is not in a position to set ceiling price of Coronary Stents due to lack of data and difference in stent pricing. Though NPPA notified that they have initiated the exercise of determination of ceiling price of Coronary Stents after they received notice from department of pharmaceuticals.
Department of Pharmaceuticals (DoP) notified that "Coronary Stents" will be included in Drugs Price Control Order (DPCO), soon. This Order may be called the Drugs (Prices Control) third amendment Order, 2016.